Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART19 for MRD in adult B-ALL
NCT02935543Phase 2Terminated
- Sponsor
- University of Pennsylvania
- Start
- Oct 2016
- Primary completion
- Dec 2018
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ARI-0001 in acute lymphoblastic leukemia (ALL), sponsored by University of Pennsylvania. Primary endpoint: Incidence of Conversion of Minimal Residual Disease (MRD) to <0.01% at 28 days. Started Oct 2016; status: terminated.
02
Drugs
ARI-0001
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02935543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02935543.